Latest Preotact Stories
NPS Pharmaceuticals has reported positive interim data from an investigator-initiated Phase II proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone for the treatment of hypoparathyroidism.
Amgen (NASDAQ:AMGN) today announced full data results from a non-pivotal Phase 3 head-to-head, double-blind trial comparing bone mineral density (BMD) gains in postmenopausal women with low bone mass who transitioned from weekly oral alendronate (Fosamax(R)) to denosumab versus those who continued alendronate therapy.
At the 30th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), positive interim data were presented from an investigator-initiated Phase 2 proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone (PTH 1-84) under development by NPS Pharmaceuticals, Inc.
Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced that an abstract detailing results of its Phase 2 study of Zosano PTH Patch, a proprietary transdermal patch formulation of parathyroid hormone (PTH) for the treatment of established osteoporosis, has been accepted as a late-breaking poster presentation at the 2008 American College of Rheumatology Annual Scientific Meeting.
MARKHAM, ON, and OSAKA, Japan, July 30 /PRNewswire/ -- Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S.
Amgen (NASDAQ: AMGN) today announced findings from the pivotal fracture trial evaluating its RANK Ligand inhibitor, denosumab, in the treatment of postmenopausal osteoporosis.
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced that twice-yearly subcutaneous injections of denosumab (60 mg), (previously referred to as AMG 162), increased bone mineral density (BMD) in the lumbar spine, total hip, distal 1/3 radius and total body compared to placebo at 24 months. The study also included an open label FosamaxÂ®* (alendronate) arm. Investigators reported on a pre-planned exploratory analysis at the American College of Rheumatology Annual...
Scientists from the Garvan Institute of Medical Research in Sydney, Australia, are suggesting a new approach to determining the risk of fracture in individuals with the brittle bone disease, osteoporosis, which could have treatment implications.
A new study found that the drug used to treat osteoporosis, when used in combination with calcium and vitamin D, can prevent the additional bone loss that commonly occurs after liver transplants. The treatment also helped stabilize bone loss in patients who already had osteoporosis, and helped improve their bone mineral density (BMD).
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.